Problematiche collegate allo screening neonatale ed alla diagnostica molecolare della fibrosi cistica

A. Cantù Rajnoldi, C. Corbetta, A. Giunta, F. Lalatta

Research output: Contribution to journalArticle

Abstract

The following topics are discussed in this consensus document on the problems arising from molecular analysis of cystic fibrosis (CF): a) neonatal screening: the application of DNA analysis in the neonatal screening for CF implies that some heterozygotes are going to be identified; pre-testing and post-testing informations need to be accurate and widespread; the possibility of withdrawing from being tested has to be guaranteed; b) popoulation heterozygote screening: the insufficient sensitivity of the molecular test, the incomplete definition of the genotype-phenotype correlations, the high costs, the relevance of psycho-social effects, the lack of laboratory quality control programs are all points against a policy of a population screening of the Italian population; c) carrier testing: this is at present performed and should be offered to relatives of CF patients or heterozygotes («cascade screening»); partners of subjects found to be positive should also be tested. The test should be preferably performed before pregnancy to allow a wider variety of options; we advice against testing in children due to is purely reproductive significance; d) prenatal diagnosis: it has a well defined role for couples with a 1:4 risk; on the contrary, the offer of prenatal diagnosis to intermediate risk couples should be discouraged in view of the impossibility to obtaine conclusive results in these cases.

Original languageEnglish
Pages (from-to)931-935
Number of pages5
JournalRivista Italiana di Pediatria
Volume23
Issue number5
Publication statusPublished - 1997

Fingerprint

Heterozygote
Cystic Fibrosis
Neonatal Screening
Prenatal Diagnosis
Genetic Association Studies
Public Policy
Quality Control
Consensus
Costs and Cost Analysis
Pregnancy
DNA
Population

Keywords

  • Carrier testing
  • Cascade testing
  • Counselling
  • Cystic fibrosis
  • Heterozygote screening
  • Neonatal screening
  • Prenatal diagnosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Problematiche collegate allo screening neonatale ed alla diagnostica molecolare della fibrosi cistica. / Cantù Rajnoldi, A.; Corbetta, C.; Giunta, A.; Lalatta, F.

In: Rivista Italiana di Pediatria, Vol. 23, No. 5, 1997, p. 931-935.

Research output: Contribution to journalArticle

@article{477a44502bfa4b9a81db1fd3d97c59ec,
title = "Problematiche collegate allo screening neonatale ed alla diagnostica molecolare della fibrosi cistica",
abstract = "The following topics are discussed in this consensus document on the problems arising from molecular analysis of cystic fibrosis (CF): a) neonatal screening: the application of DNA analysis in the neonatal screening for CF implies that some heterozygotes are going to be identified; pre-testing and post-testing informations need to be accurate and widespread; the possibility of withdrawing from being tested has to be guaranteed; b) popoulation heterozygote screening: the insufficient sensitivity of the molecular test, the incomplete definition of the genotype-phenotype correlations, the high costs, the relevance of psycho-social effects, the lack of laboratory quality control programs are all points against a policy of a population screening of the Italian population; c) carrier testing: this is at present performed and should be offered to relatives of CF patients or heterozygotes («cascade screening»); partners of subjects found to be positive should also be tested. The test should be preferably performed before pregnancy to allow a wider variety of options; we advice against testing in children due to is purely reproductive significance; d) prenatal diagnosis: it has a well defined role for couples with a 1:4 risk; on the contrary, the offer of prenatal diagnosis to intermediate risk couples should be discouraged in view of the impossibility to obtaine conclusive results in these cases.",
keywords = "Carrier testing, Cascade testing, Counselling, Cystic fibrosis, Heterozygote screening, Neonatal screening, Prenatal diagnosis",
author = "{Cant{\`u} Rajnoldi}, A. and C. Corbetta and A. Giunta and F. Lalatta",
year = "1997",
language = "English",
volume = "23",
pages = "931--935",
journal = "Rivista Italiana di Pediatria",
issn = "0392-5161",
publisher = "Pacini Editore s.r.l.",
number = "5",

}

TY - JOUR

T1 - Problematiche collegate allo screening neonatale ed alla diagnostica molecolare della fibrosi cistica

AU - Cantù Rajnoldi, A.

AU - Corbetta, C.

AU - Giunta, A.

AU - Lalatta, F.

PY - 1997

Y1 - 1997

N2 - The following topics are discussed in this consensus document on the problems arising from molecular analysis of cystic fibrosis (CF): a) neonatal screening: the application of DNA analysis in the neonatal screening for CF implies that some heterozygotes are going to be identified; pre-testing and post-testing informations need to be accurate and widespread; the possibility of withdrawing from being tested has to be guaranteed; b) popoulation heterozygote screening: the insufficient sensitivity of the molecular test, the incomplete definition of the genotype-phenotype correlations, the high costs, the relevance of psycho-social effects, the lack of laboratory quality control programs are all points against a policy of a population screening of the Italian population; c) carrier testing: this is at present performed and should be offered to relatives of CF patients or heterozygotes («cascade screening»); partners of subjects found to be positive should also be tested. The test should be preferably performed before pregnancy to allow a wider variety of options; we advice against testing in children due to is purely reproductive significance; d) prenatal diagnosis: it has a well defined role for couples with a 1:4 risk; on the contrary, the offer of prenatal diagnosis to intermediate risk couples should be discouraged in view of the impossibility to obtaine conclusive results in these cases.

AB - The following topics are discussed in this consensus document on the problems arising from molecular analysis of cystic fibrosis (CF): a) neonatal screening: the application of DNA analysis in the neonatal screening for CF implies that some heterozygotes are going to be identified; pre-testing and post-testing informations need to be accurate and widespread; the possibility of withdrawing from being tested has to be guaranteed; b) popoulation heterozygote screening: the insufficient sensitivity of the molecular test, the incomplete definition of the genotype-phenotype correlations, the high costs, the relevance of psycho-social effects, the lack of laboratory quality control programs are all points against a policy of a population screening of the Italian population; c) carrier testing: this is at present performed and should be offered to relatives of CF patients or heterozygotes («cascade screening»); partners of subjects found to be positive should also be tested. The test should be preferably performed before pregnancy to allow a wider variety of options; we advice against testing in children due to is purely reproductive significance; d) prenatal diagnosis: it has a well defined role for couples with a 1:4 risk; on the contrary, the offer of prenatal diagnosis to intermediate risk couples should be discouraged in view of the impossibility to obtaine conclusive results in these cases.

KW - Carrier testing

KW - Cascade testing

KW - Counselling

KW - Cystic fibrosis

KW - Heterozygote screening

KW - Neonatal screening

KW - Prenatal diagnosis

UR - http://www.scopus.com/inward/record.url?scp=33748013741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748013741&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748013741

VL - 23

SP - 931

EP - 935

JO - Rivista Italiana di Pediatria

JF - Rivista Italiana di Pediatria

SN - 0392-5161

IS - 5

ER -